

# <<Add Project Title Here>>: Initial Report of Data

<<List Presenters Here>>

<<Add Presentation Date Here>>



# <<Insert Project Title Here>>

*If program is accredited for CME Credit*

- Supported by
  - <<List any commercial support for this program here>>
- Disclosure
  - <<List any commercial relationships of any faculty or those in a position to control content here>>

## <<Insert Project Title Here>>

- **Stage A: Assessment of your practice**
  - Review your own vaccination rates
  - Education sessions to support assessment and change
- **Stage B: Creation of Action Plan**
  - Individual plan to change with support from experts
  - Plans to change as a group and create new systems to support your change
- **Stage C: Ongoing Chart Review**
  - Continue to review your vaccination rates and see if your practice change had the intended effect

# Next Steps *(credits refer to CME accreditation)*

- **Educational Sessions: *may be worth 1 CME/CEU credit each***
  - Vaccination Update Session
  - Motivational Interviewing
  - Practical Ways to Improve Vaccination Rates (ie. Action Plan Discussion)
- **Stage B: Creation of Action Plan**
  - 5 CME and 1 CME/CEU for education
  - Participants create/submit Individualized Action Plan.
  - Participants implement Individualized Action Plan after approval.
- **Stage C: Follow-up Chart Audit**
  - 5 CME credits

## Advisory Committee for Immunization Practices (ACIP) HPV Vaccine Recommendations, 2015<sup>27</sup>

- Routine vaccination recommended for boys and girls at age 11 or 12 y. (Vaccination series can be started at age 9 y.)
- Vaccination recommended through age 26 for females and through age 21 for males not previously vaccinated.
- Vaccination recommended through age 26 for men who have sex with men (MSM) and those who are immunocompromised (including those with HIV infection).

### Formulation by gender (assuming availability)

	9vHPV	4vHPV	2vHPV
Females	✓	✓	✓
Males	✓	✓	

---

# **REPORT OF DATA MEASURES**

## HPV Vaccine Measures: total population

- Male and Female patients aged 11-12, 13-17, and 18-26 years
- Percent with  $\geq 1$ ,  $\geq 2$ , and  $\geq 3$  HPV vaccine injections

*Denominator defined as: All patients with a visit in past 18 months*


## HPV Vaccine Measures: completion among those who started

- Male and Female patients aged 11-12, 13-17, and 18-26 years
- Percent with  $\geq 2$  HPV vaccine injections among those who started the series at least 2 months ago
- Percent with  $\geq 3$  HPV vaccine injections among those who started the series at least 6 months ago


*Denominator: Patients who initiated vaccine series*



# NIS-teen Benchmark Data USA (13-17)



# NIS-teen Benchmark Data MA (13-17)



# CHART REVIEW DATA

*Below represents a sample of one of our program's patient population*

- **Mean Patient Age: 15**

## **Racial distribution:**

- **African-American - 31%**
- **Caucasian - 14%**
- **Latino - 16%**
- **Asian - 32%**
- **Other - 7%**

## **Language distribution:**

- **English - 65%**
- **Spanish - 7%**
- **Vietnamese - 24%**
- **Portuguese - 3%**
- **Other - 1%**

## **Insurance type:**


- **Public - 63%**
- **Private - 36%**
- **Uninsured – 1%**

# CHART REVIEW DATA


Provider	n	n Girls	n Boys
Insert provider names here	le. 150	75	75
<b>TOTAL</b>			




# % of Patients with $\geq 1$ HPV Vaccine Injections



# % of Patients with $\geq 2$ HPV Vaccine Injections




# % of Patients with $\geq 3$ HPV Vaccine Injections




	N (Females)	N (Males)
<b>Initiated Vaccine at least 2 months ago</b>		
	<b>11-12</b>	
	<b>13-17</b>	
	<b>18-26</b>	
<b>Initiated Vaccine at least 6 months ago</b>		
	<b>11-12</b>	
	<b>13-17</b>	
	<b>18-26</b>	




# % with $\geq 2$ HPV vaccine injections among those who started the series $\geq 2$ months ago



# % with $\geq 3$ HPV vaccine injections among those who started the series $\geq 6$ months ago



# HEDIS Measure: % of females currently aged 13 with 3 HPV vaccine injections by their 13th birthday (n=400 girls)



# Discussion

- What aspects of your performance are you happy with?
- How have your current efforts to improve vaccination been successful?
- What opportunities for further improvement have you identified?
- Do you have any theories about why certain gaps exist?

# OTHER QUESTIONS